Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center

Rucaparib and Nivolumab in Treating Patients with Advanced or Metastatic Biliary Tract Cancer after Platinum Therapy

This phase II trial studies how well rucaparib and nivolumab work in treating patients with biliary tract cancer that has spread to other places in the body after platinum therapy. Rucaparib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving rucaparib and nivolumab after platinum therapy may help kill more cancer cells that are left after chemotherapy.
Gastrointestinal, Liver
Phase II
Adults
Mol. targeted/Immunotherapy/Biologics
Nivolumab (BMS-936558), Rucaparib
Goff, Laura
National
Vanderbilt University
08-06-2019
Treatment
VICCGI1915
NCT03639935

Eligibility

Not Available
Not Available
NO
Inclusion Criteria:

Patients must have a pathologically confirmed adenocarcinoma of the biliary tract (intra-hepatic, extra-hepatic [hilar, distal] or gall bladder) that is not eligible for curative resection, transplantation, or ablative therapies. Tumors of mixed histology are excluded.

To learn more about any of our clinical
trials, call 1-800-811-8480 or complete
the online Self-Referral Form here: